Clinical Trial Update: Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating neoadjuvant autologous tumor-infiltrating lymphocytes combined with pembrolizumab for locally advanced and metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous tumor-infiltrating lymphocytes (TIL) therapy (tumor-infiltrating lymphocytes)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Richard Wu | Conditions: Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING